Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus standard of care in previously treated extensive-stage small cell lung cancer
NL-OMON60966Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Sacituzumab govitecan with Standard of care (2 arms). Primary endpoint: Overall survival. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60966.